What Sanofi-Winthrop does

Sanofi-Winthrop, doing business as Winthrop US, is a wholly-owned business unit of Sanofi US dedicated to distributing authorized generic pharmaceuticals in the United States market. The company sells four prescription products—Docetaxel Injection Concentrate (equivalent to Taxotere), Enoxaparin Sodium Injection (equivalent to Lovenox), Sevelamer Carbonate Tablets (equivalent to Renvela), and Sevelamer Hydrochloride Tablets (equivalent to Renagel)—that are identical to Sanofi's brand-name counterparts in formulation, inactive ingredients, and manufacturing process. Winthrop US targets US Healthcare Professionals through a dedicated HCP portal on Sanofi's Pro Campus platform, with two of its four products (Docetaxel and Enoxaparin) carrying FDA boxed warnings.

The business operates a sales-led, prescription-based go-to-market model, distributing through established US pharmaceutical supply chains to retail pharmacies, hospital systems, and institutional buyers. Revenue is generated through one-time prescription sales, with pricing negotiated through pharmacy benefit managers and institutional purchasing agreements; specific pricing is not publicly disclosed. The entity is not separately publicly traded—its financials are consolidated within Sanofi SA (EPA: SAN), and no independent ownership, funding events, or private equity involvement are indicated. Operations are restricted to the United States, with the website gated to US Healthcare Professionals only, reflecting regulatory and commercial scoping.

Name

Sanofi-Winthrop

Legal name

Winthrop US

Website

https://winthropus.com

Company type

Private

Operating status

Operating

Short description

Winthrop US is a Sanofi US business unit selling four authorized generic prescription pharmaceuticals—Docetaxel, Enoxaparin Sodium, and two Sevelamer formulations—to US healthcare professionals through established pharmaceutical distribution channels.

Ownership category

akta.pro rank

Product category

Authorized Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Oral Solid Dose (OSD) Generics (HLAIABAD), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Authorized generic pharmaceuticals
• Prescription generic drugs
• Oncology generic injectables
• Anticoagulant generics
• Phosphate binder generics

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Authorized Generic Pharmaceuticals: Winthrop US generates revenue through the sale of authorized generic pharmaceuticals. These are prescription medications that are identical to Sanofi's brand name products in terms of inactive ingredients and manufacturing process, sold at more affordable price points. Revenue is derived from prescriptions filled through healthcare providers, pharmacies, and institutional buyers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Winthrop US manufactures and distributes authorized generic pharmaceuticals that are identical in formulation, inactive ingredients, and manufacturing process to Sanofi's brand-name drugs. Its portfolio comprises four featured prescription products—Docetaxel Injection Concentrate (Taxotere equivalent for oncology), Enoxaparin Sodium Injection (Lovenox equivalent for anticoagulation), Sevelamer Carbonate Tablets (Renvela equivalent for chronic kidney disease), and Sevelamer Hydrochloride Tablets (Renagel equivalent for end-stage renal disease)—sold to US healthcare professionals, pharmacies, and institutions at lower cost than the corresponding brand products.

Product overview

Winthrop US is a Sanofi company dedicated to delivering authorized generics - pharmaceutical products that are identical to Sanofi's brand name drugs in formulation, inactive ingredients, and manufacturing process. The Winthrop portfolio consists of four featured authorized generics: Docetaxel Injection Concentrate (equivalent to Taxotere), Enoxaparin Sodium Injection (equivalent to Lovenox), Sevelamer Carbonate Tablets (equivalent to Renvela), and Sevelamer Hydrochloride Tablets (equivalent to Renagel). These authorized generics provide the same quality, reliability, and efficacy as their brand equivalents while offering greater affordability for patients and healthcare providers.

Differentiator

Problem solved

Functional benefit

Products and services

• Docetaxel Injection Concentrate Authorized generic of Taxotere (docetaxel) injection concentrate for oncology treatment, sold to US healthcare professionals; carries boxed WARNING prescribing information.
• Enoxaparin Sodium Injection Authorized generic of Lovenox (enoxaparin sodium injection), an anticoagulant for prevention and treatment of blood clots; sold to US healthcare professionals with boxed WARNING prescribing information.
• Sevelamer Carbonate Tablets Authorized generic of Renvela (sevelamer carbonate) tablets for treating high phosphate levels in patients with chronic kidney disease on dialysis; sold to US healthcare professionals.
• Sevelamer Hydrochloride Tablets Authorized generic of Renagel (sevelamer hydrochloride) tablets for controlling serum phosphorus in patients with end-stage renal disease; sold to US healthcare professionals.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves2 records

Expansion highlights2 records

Direct peers

• Sandoz: Sandoz is the generics and authorized-generics arm of a major brand pharmaceutical manufacturer (formerly Novartis), and directly competes with Winthrop in the US authorized-generics market for products such as enoxaparin (where it markets the Momenta-developed generic Lovenox) and other specialty generics. Same business model (brand-quality generics distributed through established channels) and same competitive set.
• Teva Pharmaceutical Industries: Teva is the world's largest generics manufacturer and competes with Winthrop across multiple product categories including oncology (docetaxel) and injectable generics (enoxaparin class). Its broad US generics footprint and HCP relationships make it a direct peer for both products and GTM approach.
• Viatris: Viatris (the merged Mylan-Upjohn entity) is a leading US generic and specialty pharmaceutical company with a portfolio overlapping Winthrop's therapeutic areas (oncology, nephrology, anticoagulation). It competes directly on docetaxel, enoxaparin, and sevelamer generics and operates a similar HCP-targeted sales model.
• Amphastar Pharmaceuticals: Amphastar is a US specialty injectable generics company whose portfolio includes enoxaparin sodium injection - a direct head-to-head competitor to Winthrop's Enoxaparin Sodium Injection authorized generic. Its hospital-channel GTM focus makes it especially comparable on injectable product overlap.
• Amneal Pharmaceuticals: Amneal is a US-focused generics and specialty pharmaceutical manufacturer with overlapping products in oncology injectables, complex generics, and institutional channels. Its mix of branded-equivalent generics and HCP-targeted sales mirrors Winthrop's authorized-generics strategy.
• Apotex: Apotex is a large privately held Canadian generics manufacturer with significant US presence in solid-dose and injectable generics, including oncology and renal products. It is a direct competitor to Winthrop on products such as sevelamer and competes through similar pharmacy and institutional channels.
• Hikma Pharmaceuticals: Hikma is a multinational generic pharmaceutical manufacturer with a strong US injectables franchise overlapping Winthrop's oncology injectable (docetaxel) and injectable anticoagulant categories. Its hospital-channel focus makes it a direct peer in institutional sales.
• Aurobindo Pharma: Aurobindo is a major Indian-headquartered generic pharmaceutical manufacturer with extensive US approvals in solid oral dose generics (including sevelamer) and injectables. It directly competes with Winthrop on sevelamer tablets and other products where it has AB-rated generic approvals.
• Dr. Reddy's Laboratories: Dr. Reddy's is a global generics manufacturer with meaningful US presence in oncology injectables (docetaxel), injectable anticoagulants, and renal/nephrology generics. Same therapeutic overlap and same hospital-channel GTM orientation as Winthrop.
• Lannett Company: Lannett is a US-focused generic pharmaceutical company with emphasis on solid oral dose generics including renal/nephrology products. Its portfolio of affordable AB-rated generics and GTM through wholesalers/pharmacies aligns with the competitive set surrounding Winthrop's sevelamer tablets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/sanofius
• Facebookfacebook.com/sanofius

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanofi-Winthrop